Oncotarget

Precision Oncology:

Article has an altmetric score of 55

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients

Wafik S. El-Deiry _, Catherine Bresson, Fanny Wunder, Benedito A. Carneiro, Don S. Dizon, Jeremy L. Warner, Stephanie L. Graff, Christopher G. Azzoli, Eric T. Wong, Liang Cheng, Sendurai A. Mani, Howard P. Safran, Casey Williams, Tobias Meissner, Benjamin Solomon, Eitan Rubin, Angel Porgador, Guy Berchem, Pierre Saintigny, Amir Onn, Jair Bar, Raanan Berger, Manon Gantenbein, Zhen Chen, Cristiano de Pádua Souza, Rui Manuel Vieira Reis, Marina Sekacheva, Andrés Cervantes, William L. Dahut, Christina M. Annunziata, Kerri Gober, Khaled M. Musallam, Humaid O. Al-Shamsi, Ibrahim Abu-Gheida, Ramon Salazar, Sewanti Limaye, Adel T. Aref, Roger R. Reddel, Mohammed Ussama Al Homsi, Abdul Rouf, Said Dermime, Jassim Al Suwaidi, Catalin Vlad, Rares Buiga, Amal Al Omari, Hikmat Abdel-Razeq, Luis F. Oñate-Ocaña, Finn Cilius Nielsen, Leah Graham, Jens Rueter, Anthony M. Joshua, Eugenia Girda, Steven Libutti, Gregory Riedlinger, Mohammed E. Salem, Carol J. Farhangfar, Ruben A. Mesa, Bishoy M. Faltas, Olivier Elemento, C.S. Pramesh, Manju Sengar, Satoru Aoyama, Sadakatsu Ikeda, Ioana Berindan-Neagoe, Himabindu Gaddipati, Mandar Kulkarni, Elisabeth Auzias, Maria Gerogianni, Nicolas Wolikow, Simon Istolainen, Pessie Schlafrig, Naftali Z. Frankel, Amanda R. Ferraro, Jim Palma, Alejandro Piris Gimenez, Alberto Hernando-Calvo, Enriqueta Felip, Apostolia M. Tsimberidou, Roy S. Herbst, Josep Tabernero, Richard L. Schilsky, Jia Liu, Yves Lussier, Jacques Raynaud, Gerald Batist, Shai Magidi and Razelle Kurzrock

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2025; 16:140-162. https://doi.org/10.18632/oncotarget.28703

Metrics: PDF 1307 views  |   Full Text 2224 views  |   ?  


Abstract

Wafik S. El-Deiry1,2, Catherine Bresson1, Fanny Wunder1, Benedito A. Carneiro2, Don S. Dizon2, Jeremy L. Warner2, Stephanie L. Graff2, Christopher G. Azzoli2, Eric T. Wong2, Liang Cheng2, Sendurai A. Mani2, Howard P. Safran2, Casey Williams3, Tobias Meissner3, Benjamin Solomon3, Eitan Rubin4, Angel Porgador4, Guy Berchem5,6,7, Pierre Saintigny8,9, Amir Onn10, Jair Bar10,11, Raanan Berger10, Manon Gantenbein7, Zhen Chen12, Cristiano de Pádua Souza13, Rui Manuel Vieira Reis13,14, Marina Sekacheva15, Andrés Cervantes16, William L. Dahut17, Christina M. Annunziata17, Kerri Gober17, Khaled M. Musallam18, Humaid O. Al-Shamsi18, Ibrahim Abu-Gheida18, Ramon Salazar19, Sewanti Limaye20, Adel T. Aref21, Roger R. Reddel21, Mohammed Ussama Al Homsi22, Abdul Rouf22, Said Dermime22, Jassim Al Suwaidi22, Catalin Vlad23, Rares Buiga23, Amal Al Omari24, Hikmat Abdel-Razeq24, Luis F. Oñate-Ocaña25, Finn Cilius Nielsen26, Leah Graham27, Jens Rueter27, Anthony M. Joshua28,29, Eugenia Girda30, Steven Libutti30, Gregory Riedlinger30, Mohammed E. Salem31, Carol J. Farhangfar31, Ruben A. Mesa31, Bishoy M. Faltas32, Olivier Elemento32, C.S. Pramesh33, Manju Sengar33, Satoru Aoyama34, Sadakatsu Ikeda34, Ioana Berindan-Neagoe35,36, Himabindu Gaddipati37, Mandar Kulkarni37, Elisabeth Auzias38, Maria Gerogianni38, Nicolas Wolikow38, Simon Istolainen38, Pessie Schlafrig39, Naftali Z. Frankel39, Amanda R. Ferraro40, Jim Palma41, Alejandro Piris Gimenez42, Alberto Hernando-Calvo42, Enriqueta Felip42, Apostolia M. Tsimberidou43, Roy S. Herbst44, Josep Tabernero42, Richard L. Schilsky45, Jia Liu21,28,29, Yves Lussier1,46, Jacques Raynaud1, Gerald Batist47, Shai Magidi1 and Razelle Kurzrock1,48

1 Worldwide Innovative Network (WIN) Association – WIN Consortium, Chevilly-Larue, France

2 Legorreta Cancer Center at Brown University, Providence, RI 02912, USA

3 Avera Cancer Institute, Sioux Falls, SD 57105, USA

4 Ben-Gurion University of the Negev, Be'er Sheva, Israel

5 Centre Hospitalier du Luxembourg, Luxembourg

6 University of Luxembourg, Esch-sur-Alzette, Luxembourg

7 Luxembourg Institute of Health, Luxembourg

8 Department of Medical Oncology, Centre Léon Bérard, Lyon, France

9 University of Lyon, Claude Bernard Lyon 1 University, INSERM 1052, CNRS 5286, Centre Léon Bérard, Cancer Research Center of Lyon, Lyon, France

10 Jusidman Cancer Center, Sheba Medical Center, Ramat Gan, Israel

11 Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel

12 Fudan University Shanghai Cancer Center, Shanghai, China

13 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, Brazil

14 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal

15 I.M Sechenov First Medical State University, Moscow, Russian Federation

16 INCLIVA Instituto de Investigación Sanitaria, Valencia, Spain

17 American Cancer Society, Atlanta, Georgia, MD 21742, USA

18 Burjeel Medical City (BMC), Mohamed Bin Zayed City, Abu Dhabi, UAE

19 Medical Oncology Deparment. Institut Català d'Oncologia. Oncobell Program (IDIBELL), Universitat de Barcelona (Campus Bellvitge), CIBERONC, Barcelona, Spain

20 Sir H.N. Reliance Foundation Hospital and Research Centre, Mumbai, India

21 ProCan, Children’s Medical Research Institute, The University of Sydney, Australia

22 National Center for Cancer Care and Research Hamad Medical Corporation, Doha, Qatar

23 Oncology Institute Ion Chiricuta, Cluj, Romania

24 King Hussein Cancer Center, Amman, Jordan

25 Instituto Nacional de Cancerología (INCan), Mexico City, Mexico

26 Rigshospitalet, Copenhagen, Denmark

27 The Jackson Laboratory, The Maine Cancer Genomics Initiative, Bar Harbor, ME 04609, USA

28 The Kinghorn Cancer Centre, St Vincent’s Hospital, Darlinghurst, Australia

29 School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia

30 Rutgers Cancer Institute, New Brunswick, NJ 08901, USA

31 Wake Forest University Health Sciences/Atrium Health (WFUHS), Winston-Salem, NC 27157, USA

32 Weill Cornell Medical College, NY 10065, USA

33 Tata Memorial Centre, Affiliated to Homi Bhabha National Institute, Mumbai, India

34 Institute of Science Tokyo Hospital, Tokyo, Japan

35 University of Medicine and Pharmacy Iuliu Hatieganu, Cluj, Romania

36 Academy of Medical Sciences, Bucharest, Romania

37 Vyas Cancer Research (VCR Park), Maharanipeta, Visakhpatnam, Andhra Pradesh, India

38 Cure51, Paris, France

39 CHAIM Medical Resource Organization, NY 10950, USA

40 Cancer is an A*, LLC, Manalapan Township, NJ 07726, USA

41 TargetCancer Foundation, Cambridge, MA 02139, USA

42 Vall d’Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain

43 The University of Texas, M.D. Anderson Cancer Center, Houston, TX 77030, USA

44 Yale School of Medicine, New Haven, CT 06510, USA

45 The University of Chicago, Chicago, IL 60637, USA

46 The University of Utah, Salt Lake City, UT 84112, USA

47 Segal Cancer Centre, Jewish Hospital, McGill University, Montreal, Quebec, Canada

48 Medical College of Wisconsin, Milwaukee, WI 53226, USA

Correspondence to:

Wafik S. El-Deiry, email: wafik@brown.edu

Keywords: precision oncology; N-of-1 basket trials; AI algorithms; digital pathology; drug access

Received: December 30, 2024     Accepted: February 27, 2025     Published: March 12, 2025

Copyright: © 2025 El-Deiry et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity—including financial and time—are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN’s collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28703